255 related articles for article (PubMed ID: 35889373)
1. Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases.
Hu X; Wang X; Xue X
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889373
[TBL] [Abstract][Full Text] [Related]
2. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.
Klemann C; Wagner L; Stephan M; von Hörsten S
Clin Exp Immunol; 2016 Jul; 185(1):1-21. PubMed ID: 26919392
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.
Nishina S; Yamauchi A; Kawaguchi T; Kaku K; Goto M; Sasaki K; Hara Y; Tomiyama Y; Kuribayashi F; Torimura T; Hino K
Cell Mol Gastroenterol Hepatol; 2019; 7(1):115-134. PubMed ID: 30510994
[TBL] [Abstract][Full Text] [Related]
4. The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNS - a critical overview.
Bernstein HG; Keilhoff G; Dobrowolny H; Steiner J
Rev Neurosci; 2023 Jan; 34(1):1-24. PubMed ID: 35771831
[TBL] [Abstract][Full Text] [Related]
5. CD26: a multi-purpose pharmacological target.
Vincenzo F; Manfredi T; Carmine C; Mario R
Curr Clin Pharmacol; 2014 May; 9(2):157-64. PubMed ID: 24219003
[TBL] [Abstract][Full Text] [Related]
6. The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity.
Jang JH; Janker F; De Meester I; Arni S; Borgeaud N; Yamada Y; Gil Bazo I; Weder W; Jungraithmayr W
Carcinogenesis; 2019 Apr; 40(2):324-334. PubMed ID: 30698677
[TBL] [Abstract][Full Text] [Related]
7. Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis.
Ohm B; Moneke I; Jungraithmayr W
Br J Pharmacol; 2023 Nov; 180(22):2846-2861. PubMed ID: 36196001
[TBL] [Abstract][Full Text] [Related]
8. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease.
Zhong J; Rao X; Rajagopalan S
Atherosclerosis; 2013 Feb; 226(2):305-14. PubMed ID: 23083681
[TBL] [Abstract][Full Text] [Related]
9. Degranulation of human cytotoxic lymphocytes is a major source of proteolytically active soluble CD26/DPP4.
Lettau M; Dietz M; Vollmers S; Armbrust F; Peters C; Dang TM; Chitadze G; Kabelitz D; Janssen O
Cell Mol Life Sci; 2020 Feb; 77(4):751-764. PubMed ID: 31300870
[TBL] [Abstract][Full Text] [Related]
10. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.
Zhong J; Maiseyeu A; Davis SN; Rajagopalan S
Circ Res; 2015 Apr; 116(8):1491-504. PubMed ID: 25858071
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase in autoimmune pathophysiology.
Ohnuma K; Hosono O; Dang NH; Morimoto C
Adv Clin Chem; 2011; 53():51-84. PubMed ID: 21404914
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions.
Shao S; Xu Q; Yu X; Pan R; Chen Y
Pharmacol Ther; 2020 May; 209():107503. PubMed ID: 32061923
[TBL] [Abstract][Full Text] [Related]
13. A novel multi-epitope vaccine based on Dipeptidyl Peptidase 4 prevents streptozotocin-induced diabetes by producing anti-DPP4 antibody and immunomodulatory effect in C57BL/6J mice.
Li Z; Fang J; Jiao R; Wei X; Ma Y; Liu X; Cheng P; Li T
Biomed Pharmacother; 2017 May; 89():1467-1475. PubMed ID: 28376584
[TBL] [Abstract][Full Text] [Related]
14. CD26/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leukcocyte subsets in F344-rats age-dependently.
Klemann C; Schade J; Pabst R; Leitner S; Stiller J; von Hörsten S; Stephan M
Clin Exp Immunol; 2009 Feb; 155(2):357-65. PubMed ID: 19055685
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism.
Mulvihill EE
Peptides; 2018 Feb; 100():158-164. PubMed ID: 29412815
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory activity of dipeptidyl peptidase-4 inhibitors in immune-related diseases.
Drakul M; Čolić M
Eur J Immunol; 2023 Dec; 53(12):e2250302. PubMed ID: 37732495
[TBL] [Abstract][Full Text] [Related]
17. Degradation of Incretins and Modulation of Blood Glucose Levels by Periodontopathic Bacterial Dipeptidyl Peptidase 4.
Ohara-Nemoto Y; Nakasato M; Shimoyama Y; Baba TT; Kobayakawa T; Ono T; Yaegashi T; Kimura S; Nemoto TK
Infect Immun; 2017 Sep; 85(9):. PubMed ID: 28630069
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
19. Incretins yesterday, pleiotropic gastrointestinal hormones today:glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Kiec-Klimczak ME; Pach DM; Pogwizd ME; Hubalewska-Dydejczyk AB
Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):176-82. PubMed ID: 21913887
[TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory effects on ischemia/reperfusion-injured lung transplants by the cluster of differentiation 26/dipeptidylpeptidase 4 (CD26/DPP4) inhibitor vildagliptin.
Jang JH; Yamada Y; Janker F; De Meester I; Baerts L; Vliegen G; Inci I; Chatterjee S; Weder W; Jungraithmayr W
J Thorac Cardiovasc Surg; 2017 Mar; 153(3):713-724.e4. PubMed ID: 27939504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
